Entropy Neurodynamics Limited has released a press release.
Exopharm Receives Firm Commitments to Raise $12 million
Filed with ASX ·
6ix hasn’t read this filing yet.
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- Positive PLEXOVAL II Phase 1 Clinical Trial Results
- Preclinical Data from Osteoarthritis Animal Study
- Appendix 4D and Half Year Financial Report
- Response to ASX Price and Volume Query
- Quarterly Report and Appendix 4C
Later from Entropy Neurodynamics
- Exopharm LEAP Exosome Technology Granted 1st National Patent
- FY2021 Appendix 4E and Annual Report
- Exopharm LEAP Technology - Second Commercial Collaboration
- Exopharm LEAP Technology - Further Step Towards US Patent
- Exopharm Gains US Patent for LEAP Technology
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics